"how much money do they have to develop the IP. If they didn't get minimum guarantee spending annually on the IP then it is a bad deal"
I think that question was already addressed this morning, but for those that may have forgot.
"We believe that PS targeting possesses significant promise in the treatment of cancer and look forward to highlighting the therapeutic potential of the approach THROUGH INNOVATIVE CLINICAL TRIALS. To this end, WE INTEND TO CONTINUE ONGOING COLLABORATIONS with the current investigators who are overseeing investigator-initiated trials, as well as NCCN-sponsored studies, designed to evaluate the immune modulating potential of bavituximab.”
Market Data 
Markets 
AI
